The role of 5-HT2A and 5-HT2C receptors in the signal attenuation rat model of obsessive-compulsive disorder

被引:44
作者
Flaisher-Grinberg, Shlomit [1 ]
Klavir, Oded [1 ]
Joel, Daphna [1 ]
机构
[1] Tel Aviv Univ, Dept Psychol, IL-69978 Tel Aviv, Israel
基金
以色列科学基金会;
关键词
extinction; obsessive-compulsive disorder (OCD); post-training signal attenuation; rat;
D O I
10.1017/S146114570800847X
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Serotonin 5-HT2A and 5-HT2C receptors have been implicated in the pathophysiology of obsessive-compulsive disorder (OCD) and in the mechanism mediating the anti-compulsive effects of serotonin reuptake inhibitors. Yet it is currently unclear whether activation or blockade of these receptors would have an anti-compulsive effect. The present study tested the effects of 5-HT2A and 5-HT2C activation and blockade in the signal attenuation rat model of OCD. In this model, 'compulsive' behaviour is induced by attenuating a signal indicating that a lever-press response was effective in producing food. Experiments 1-4 revealed that systemic administration of the 5-HT2C antagonist RS 102221 (2 mg/kg) selectively decreases compulsive lever-pressing, whereas systemic administration of the 5-HT2A antagonist MDL 11,939 (0.2-5 mg/kg) or of the 5-HT2A/2C agonist DOI (0.05-5 mg/kg) did not have a selective effect on this behaviour. Experiments 5 and 6 found that systemic co-administration of DOI (0.5 mg/kg) with MDL 11,939 (1 mg/kg) or with RS 102221 (2 mg/kg) had a non-selective effect on lever-press responding, with the former manipulation increasing and the latter manipulation decreasing lever-pressing. Finally, experiment 7 demonstrated that administration of RS 102221 directly into the orbitofrontal cortex also exerts an anti-compulsive effect. The results of these experiments suggest that blockade of 5-HT2C receptors may have an anti-compulsive effect in OCD patients, and that this effect may be mediated by 5-HT2C receptors within the orbitofrontal cortex.
引用
收藏
页码:811 / 825
页数:15
相关论文
共 77 条
[1]   Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT2A and 5-HT2C receptors [J].
Acuña-Castillo, C ;
Villalobos, C ;
Moya, PR ;
Sáez, P ;
Cassels, BK ;
Huidobro-Toro, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (04) :510-519
[2]   Neurobiologic processes in drug reward and addiction [J].
Adinoff, B .
HARVARD REVIEW OF PSYCHIATRY, 2004, 12 (06) :305-320
[3]  
Albert U, 2002, PANMINERVA MED, V44, P83
[4]  
Aloyo VJ, 2001, J PHARMACOL EXP THER, V299, P1066
[5]  
[Anonymous], 1994, AM PSYCHIATR ASSOC
[6]   A review of central 5-HT receptors and their function [J].
Barnes, NM ;
Sharp, T .
NEUROPHARMACOLOGY, 1999, 38 (08) :1083-1152
[7]   5-HT2 RECEPTOR SUBTYPES - A FAMILY RE-UNITED [J].
BAXTER, G ;
KENNETT, G ;
BLANEY, F ;
BLACKBURN, T .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (03) :105-110
[8]   5-HT2C receptor agonists as potential drugs for the treatment of obesity [J].
Bickerdike, MJ .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (08) :885-897
[9]   RS-102221: A novel high affinity and selective, 5-HT2C receptor antagonist [J].
Bonhaus, DW ;
Weinhardt, KK ;
Taylor, M ;
Desouza, A ;
Mcneeley, PM ;
Szczepanski, K ;
Fontana, DJ ;
Trinh, J ;
Rocha, CL ;
Dawson, MW ;
Flippin, LA ;
Eglen, RM .
NEUROPHARMACOLOGY, 1997, 36 (4-5) :621-629
[10]   Absorption and brain penetration of a high affinity, highly selective 5-HT2C receptor antagonist, RS-102221 [J].
Bonhaus, DW ;
Rocha, CL ;
Dawson, MW ;
Eglen, RM .
ADVANCES IN SEROTONIN RECEPTOR RESEARCH: MOLECULAR BIOLOGY, SIGNAL TRANSDUCTION, AND THERAPEUTICS, 1998, 861 :269-269